Advice
in the absence of a submission from the holder of the marketing authorisation:
isatuximab (Sarclisa®) is not recommended for use within NHSScotland.
Indication under review: in combination with bortezomib, lenalidomide, and dexamethasone, for the induction treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result, we cannot recommend its use within NHSScotland
Download detailed advice284KB (PDF)
Medicine details
- Medicine name:
- isatuximab (Sarclisa®)
- SMC ID:
- SMC2914
- Indication:
In combination with pemetrexed and platinum chemotherapy for the first‑line treatment of adults with unresectable non-epithelioid malignant pleural mesothelioma.
- Pharmaceutical company
- Sanofi
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 09 March 2026